Claims
- 1. A computer-based method of identifying an antibody that inhibits infection, the method requiring the use of a programmed computer comprising a processor and an input device, the method comprising:
(a) providing the nucleic acid sequence of a plurality of open reading frames in the genome of an infectious microorganism (b) inputting to the input device the nucleic acid sequence; (c) screening the nucleic acid sequence, using the processor, to identify an open reading frame encoding a protein that is predicted to be expressed on the surface of the infectious microorganism; (d) producing an antibody that binds to the ectodomain of the protein; and (e) determining whether the antibody inhibits the pathogenicity of the infectious microorganism.
- 2. A process of manufacturing a compound, the process comprising: carrying out the method of claim 1; and, after determining that the antibody inhibits the pathogenicity of the infectious microorganism, manufacturing a compound comprising at least a portion of the ectodomain.
- 3. A process of manufacturing an antibody, the process comprising: carrying out the method of claim 1; and, after determining that the antibody inhibits the pathogenicity of the infectious microorganism, manufacturing the antibody.
- 4. The method of claim 1, wherein the open reading frame is identified as encoding a protein expressed on the surface of the infectious microorganism by a process comprising detecting, in the open reading frame, a nucleotide sequence encoding a putative transmembrane region.
- 5. The method of claim 4, wherein the process further comprises detecting, in the open reading frame, a nucleotide sequence encoding a putative signal peptide.
- 6. The method of claim 1, wherein the open reading frame is identified as encoding a protein expressed on the surface of the infectious microorganism by detecting, in the open reading frame, a nucleotide sequence encoding a glycosylphosphatidyl inositol (GPI) linkage site.
- 7. The method of claim 1, wherein the antibody is produced by immunizing an animal with a polypeptide comprising the ectodomain of the protein.
- 8. The method of claim 1, wherein the antibody is produced by immunizing an animal with cells transfected or transduced with a nucleic acid encoding a polypeptide comprising the ectodomain of the protein.
- 9. The method of claim 1, wherein the antibody is a monoclonal antibody.
- 10. The method of claim 1, wherein the antibody is a polyclonal antibody.
- 11. The method of claim 1, wherein the infectious microorganism is a virus.
- 12. The method of claim 11, wherein the virus is variola major virus.
- 13. The method of claim 11, wherein the virus is variola minor virus.
- 14. The method of claim 11, wherein the virus is vaccinia virus.
- 15. The method of claim 11, wherein the virus is selected from the group consisting of hepatitis virus A-E, human papilloma virus, human immunodeficiency virus 1, human T cell lymphotropic virus 1, Herpes virus, Dengue virus 1-4, Ebola virus, Marburg virus, Lassa virus, Machupo virus, and influenza virus.
- 16. The method of claim 1, wherein the infectious microorganism is a bacterium.
- 17. The method of claim 16, wherein the bacterium is Mycobacterium tuberculosis.
- 18. The method of claim 16, wherein the bacterium is Mycobacterium leprae.
- 19. The method of claim 16, wherein the bacterium is a Salmonella bacterium.
- 20. The method of claim 19, wherein the Salmonella bacterium is Salmonella typhimurium or Salmonella typhi.
- 21. The method of 16, wherein the bacterium is Yersinia pestis.
- 22. The method of claim 1, wherein the infectious microorganism is a protozoan parasite.
- 23. The method of claim 22, wherein the protozoan parasite is a malarial parasite.
- 24. The method of claim 22, wherein the protozoan parasite is Leishmania.
- 25. A compound manufactured by the process of claim 2.
- 26. A method of inducing an immune response in an animal, the method comprising performing steps (a)-(e) of claim 1 and, after determining that the antibody inhibits pathogenicity of the infectious microorganism, administering a compound comprising at least a portion of the ectodomain to an animal susceptible to infection with the infectious microorganism.
- 27. The method of claim 26, wherein the immune response is a protective immune response.
- 28. The method of claim 26, wherein the compound is administered parenterally to the animal.
- 29. The method of claim 26, wherein the compound is administered to the animal intranasally, transcutaneously, or orally.
- 30. A method of treatment, the method comprising performing steps (a)-(e) of claim 1 and, after determining that the antibody inhibits pathogenicity of the infectious microorganism, administering the antibody to an animal.
- 31. An antibody manufactured by the process of claim 3.
- 32. The method of claim 8, wherein the cells express the polypeptide on their surfaces.
- 33. The method of claim 8, wherein the cells secrete the polypeptide.
- 34. The method of claim 16, wherein the bacterium is selected from the group consisting of Bacillus anthracis, Clostridium botulinum, Francisella tularensis, Corynebacterium diphtheriae, Vibrio cholerae, and Escherichia coli.
- 35. The method of claim 30, wherein the infectious microorganism is a virus.
- 36. The method of claim 35, wherein the virus is an orthopox virus.
- 37. The method of claim 35, wherein the orthopox virus is a variola virus.
- 38. The method of claim 35, wherein the orthopox virus is a vaccinia virus.
- 39. The method of claim 36, wherein the protein is a smallpox growth factor (SPGF) or a VGF (vaccinia growth factor).
- 40. The method of claim 30, wherein the antibody is a monoclonal antibody.
- 41. The method of claim 30, wherein the antibody is a polyclonal antibody.
- 42. The method of claim 36, wherein the antibody is a monoclonal antibody.
- 43. The method of claim 42, wherein the monoclonal antibody is the 3D4R-13E8 monoclonal antibody (ATCC Accession No: PTA-5040).
- 44. The method of claim 42, wherein the monoclonal antibody is the 3D4R-11D7 monoclonal antibody (ATCC Accession No: PTA-5039).
- 45. A monoclonal antibody that binds to a protein encoded by the genome of variola virus or a vaccinia virus, wherein the protein is a protein that is expressed on the surface of the virus or on the surface of a cell infected with the virus.
- 46. The monoclonal antibody of claim 45, wherein the protein is a SPGF or a VGF.
- 47. The monoclonal antibody of claim 46, wherein the monoclonal antibody is the 3D4R-13E8 monoclonal antibody (ATCC Accession No: PTA-5040).
- 48. The antibody of claim 46, wherein the monoclonal antibody is the 3D4R-11D7 monoclonal antibody (ATCC Accession No: PTA-5039).
- 49. A humanized antibody derived from the antibody of claim 47.
- 50. A humanized antibody derived from the antibody of claim 48.
- 51. The method of claim 30, further comprising administering to the animal one or more additional antibodies, wherein the one or more additional antibodies bind to a protein encoded by the infectious microorganism.
- 52. The method of claim 36, further comprising administering to the animal one or more additional antibodies, wherein the one or more additional antibodies bind to a protein encoded by the orthopox virus.
- 53. The method of claim 52, wherein the one or more additional antibodies is the 3D4R-13E8 monoclonal antibody (ATCC Accession No.: PTA-5040) or the 3D4R-11D7 monoclonal antibody (ATCC Accession No: 5039).
Parent Case Info
[0001] This application claims benefit of U.S. Provisional Application Serial No. 60/380,055, filed May 6, 2002, and U.S. Provisional Application Serial No. 60/453,649, filed Mar. 11, 2003. The disclosures of U.S. Provisional Application Serial No. 60/380,055 and U.S. Provisional Application Serial No. 60/453,649 are incorporated herein by reference in their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60380055 |
May 2002 |
US |
|
60453649 |
Mar 2003 |
US |